Previous 10 | Next 10 |
2023-06-19 05:16:46 ET Summary Pharma/biotechnology and healthcare providers are slightly undervalued relative to 11-year averages. Healthcare equipment is the most overvalued subsector. Fast facts on PBE, a genomics ETF. 10 healthcare stocks cheaper than their peers in Ju...
First-of-its-kind distribution and warehouse center introduces a holistic approach to operations and energy management Facility poised to support United Therapeutics’ near-term growth objective of doubling its revenue run rate to $4 billion annually by the middle of this decade ...
2023-05-10 10:47:03 ET Summary MannKind Corporation is a U.S. biopharmaceutical developer and marketer of inhaled therapeutics for endocrine and rare lung diseases in the United States. MannKind topped analysts on earnings and revenues on a strong increase in revenue thanks to rob...
2023-05-04 16:37:47 ET Summary United Therapeutics Corporation came in with a strong topline in Q1 FY'23, growing 10% YoY. The Tyvaso label was the star, growing 40% or $66mm over the 12 months. This shrugs off major threats from the label's competitors. The market has rew...
2023-05-03 15:06:09 ET United Therapeutics Corporation (UTHR) Q1 2023 Earnings Conference Call May 03, 2023, 09:00 AM ET Company Participants Dewey Steadman - Head-Investor Relations Martine Rothblatt - Chairperson and Chief Executive Officer Michael Benkowitz - ...
2023-05-03 06:05:34 ET United Therapeutics press release ( NASDAQ: UTHR ): Q1 GAAP EPS of $4.86 beats by $0.36 . Revenue of $506.9M (+9.7% Y/Y) misses by $7.47M . “The hard work and determination of our over 1,000 Unitherians during the first quarter of ...
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2023. Total revenues in the first quarter of 2023 grew 10% year-over-year to $506.9 million, compared to $461.9 million in the first quarter of 2022....
2023-05-02 13:05:01 ET United Therapeutics ( NASDAQ: UTHR ) is scheduled to announce Q1 earnings results on Wednesday, May 3rd, before market open. The consensus EPS Estimate is $4.71 (-6.4% Y/Y) and the consensus Revenue Estimate is $514.37M (+11.4% Y/Y). Over the las...
United Therapeutics Corporation (Nasdaq: UTHR ) announced today that it will report its first quarter 2023 financial results before the market opens on Wednesday, May 3, 2023. United Therapeutics will host a public webcast Wednesday, May 3, 2023, at 9:00 a.m. Eastern Time. The webcast wil...
Results from the EXPEDITE study of Remodulin ® induction prior to Orenitram ® therapy to be presented at ATS Baseline patient data from the TETON studies of Tyvaso ® Inhalation Solution in patients with idiopathic pulmonary fibrosis to be presented at AT...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...